HomeCompoundsGHRP-2
GHRP / GHS-R agonistWADA

GHRP-2.

Also known as: Pralmorelin · KP-102

Dosing, side-effect comparison vs. ipamorelin, and the use case for older-gen GHRPs.

EP
Researched and edited by the Epti editorial team
Every claim labeled by confidence tier · reviewed quarterly · last updated May 20, 2026
01 · Quick Overview

Quick Overview.

GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide that stimulates the pituitary gland to release growth hormone by binding to the ghrelin receptor (GHSR-1a). It is the second-generation GHRP, more potent than GHRP-6 but less potent than Hexarelin. Crucially, GHRP-2 produces a moderate elevation in cortisol and prolactin — less than Hexarelin but more than Ipamorelin. [2]

GHRP-2 is notable for being the only GHRP that has been approved as a diagnostic agent in Japan (under the brand name Pralmorelin) for testing pituitary GH reserve. [3] This gives it a more robust clinical data set than most other GHRPs.

Who it is for:

  • Intermediate users seeking a potent GH pulse with a moderate side effect profile.
  • Those who want more GH stimulation than Ipamorelin but less cortisol/prolactin elevation than Hexarelin.
  • Users interested in the diagnostic-grade compound with the most clinical data in the GHRP class.

Who it is NOT for:

  • Beginners (Ipamorelin is a safer starting point).
  • Those with cortisol or prolactin sensitivity.
  • Tested athletes (banned by WADA).
epti
Track your protocol

Turn this protocol into your actual schedule.

Log every dose, every side-effect, and every PR on one timeline.

Join waitlist →
02 · The Protocol & Usage Guide

The Protocol & Usage Guide.

Before You Start: The Checklist

  • Baseline Bloodwork: IGF-1, AM cortisol, prolactin, fasting glucose.
  • Supplies: Insulin syringes (31G, 5/16"), bacteriostatic water, alcohol swabs.
  • Reconstitution: Add 2 mL bacteriostatic water to a 2 mg vial = 1000 mcg/mL.

Standard Dosing Protocols

Experience LevelDoseFrequencyNotes
Beginner100 mcg1-2x/dayStart here to assess cortisol/prolactin response. community
Intermediate100-200 mcg2-3x/dayMost common community protocol. community
Advanced200 mcg3x/dayDiminishing returns above 200 mcg per injection. community

Note: Like all GHRPs, GHRP-2 exhibits a saturation dose of approximately 1-2 mcg/kg. Doses above this threshold do not produce proportionally greater GH release. well-established [2]

Injection Timing & Fasting

  • Inject on an empty stomach (2 hours fasted) for maximum GH pulse.
  • Avoid eating for 30-60 minutes post-injection.
  • Best times: upon waking, pre-workout, or before bed.

Cycle Length

  • Standard Cycle: 8 to 12 weeks. community
  • Time Off: 4 to 8 weeks off between cycles. community

Missed Dose Protocol

Skip the missed dose and resume the next scheduled injection. Do not double dose.

04 · Safety, Interactions & Side Effect Management

Safety, Interactions & Side Effect Management.

Side Effect Profile

Side EffectSeverityFrequencyManagement
Increased hunger / appetiteModerateCommonExpected; manage with dietary discipline.
Cortisol elevationMild to ModerateCommonMonitor AM cortisol.
Prolactin elevationMild to ModerateCommonMonitor prolactin.
Fatigue / lethargyMildCommonOften resolves after the first week.
Water retentionMildCommonReduce sodium intake.
Facial flushingMildUncommonTransient.

Contraindications

  • Absolute: Active malignancy, history of cancer, known hypersensitivity.
  • Relative: Pre-existing elevated cortisol or prolactin.

Red Flags

Discontinue and consult a physician if:

  • Prolactin >25 ng/mL (men) or >30 ng/mL (women).
  • AM cortisol consistently elevated above the normal reference range.

Pregnancy, Lactation & Fertility

  • Pregnancy: Contraindicated. No human data.
  • Lactation: Unknown; use not recommended.
  • Fertility: Elevated prolactin can suppress LH/FSH. Monitor if using long-term.
05 · Common Stacks & Combinations

Common Stacks & Combinations.

Synergistic Stacks

  • GHRP-2 + CJC-1295 (No DAC): The most common community stack. GHRP-2 (GHRP) + CJC-1295 (GHRH) produce a synergistic GH pulse. community
  • GHRP-2 + Ipamorelin: Some users combine GHRP-2's potency with Ipamorelin's selectivity to balance GH output and side effects. community

Anti-Pattern Stacks (What to Avoid)

StackSeverityRationale
GHRP-2 + HexarelinHighCombining two potent GHRPs dramatically increases cortisol and prolactin without proportional GH benefit.
GHRP-2 + MK-677ModerateBoth stimulate the GH axis; combining significantly increases water retention and insulin resistance risk.
06 · Body Composition & Training Guide

Body Composition & Training Guide.

Expected Trajectory

TimelineExpected Effects
Week 1Increased hunger, improved sleep quality, possible water retention.
Weeks 2-4Improved recovery, increased training volume capacity.
Weeks 4-12Subtle improvements in lean mass and reduction in subcutaneous fat.

Training Contexts

  • Strength/Hypertrophy: Supports recovery and lean mass accrual when stacked with a GHRH.
  • Fat Loss: Elevated GH promotes lipolysis; most effective in a moderate caloric deficit.
07 · Storage, Handling & Accessibility

Storage, Handling & Accessibility.

  • Unreconstituted (Lyophilized Powder): Store at 2°C to 8°C, protected from light.
  • Reconstituted: Refrigerate at 2°C to 8°C. Use within 30 days.
  • Beyond Use Date (BUD): 30 days refrigerated. community
  • Accessibility: Not FDA-approved for human use. Available as a research chemical. Approved as a diagnostic agent in Japan (Pralmorelin). Banned by WADA.
08 · Bloodwork Monitoring Guide

Bloodwork Monitoring Guide.

Note: Always share peptide usage with your primary care physician. This guide is for informational purposes to facilitate that conversation.

Baseline Panel (Before starting)

  • IGF-1
  • AM Cortisol
  • Prolactin
  • Fasting Glucose

Mid-Cycle Panel (Week 6)

  • IGF-1 (verify efficacy)
  • AM Cortisol (monitor for elevation)
  • Prolactin (monitor for elevation)

Post-Cycle Panel (4 weeks after cessation)

  • IGF-1
  • AM Cortisol
  • Prolactin
09 · Comparison to Similar Compounds

Comparison to Similar Compounds.

CompoundGH PotencyCortisol/ProlactinHungerClinical DataWhen to Pick
GHRP-2HighModerateModerateDiagnostic approval (Japan)Potent GH release with moderate side effects; best clinical data in class.
GHRP-6ModerateModerateVery HighAnimal modelsWhen appetite stimulation is a desired benefit.
HexarelinHighestHighModerateHuman cardiac dataShort-term maximum GH pulse.
IpamorelinModerateMinimalMinimalHuman PK studyBeginners; long-term use.
10 · Deep Dive (For Advanced Researchers)

Deep Dive (For Advanced Researchers).

Mechanism of Action

GHRP-2 is a synthetic hexapeptide that acts as a potent agonist of the ghrelin receptor (GHSR-1a) in the anterior pituitary and hypothalamus. Binding to GHSR-1a stimulates the synthesis and pulsatile release of endogenous growth hormone. [1] [6] Unlike Hexarelin, GHRP-2 does not significantly antagonise somatostatin [8], which partially explains its lower potency relative to Hexarelin. GHRP-2 also stimulates the release of cortisol and prolactin via GHSR-1a, though to a lesser degree than Hexarelin. [2] [7]

Clinical Trial Data

StudyDesignKey Findings
Bowers 1991 [1]Phase 1 (n=12)GHRP-2 produced dose-dependent GH release; 1 mcg/kg was the maximally effective dose in adults.
Pong 1996 [4]Receptor binding studyConfirmed GHRP-2 binds to GHSR-1a with high affinity; Ki = 1.8 nM.
Arvat 2001 [5]Comparative studyGHRP-2 produced greater GH release than ghrelin at equivalent doses in healthy adults.
Pralmorelin (Japan) [3]Diagnostic useApproved in Japan as a GH stimulation test agent at 2 mcg/kg IV.

Active Metabolites

GHRP-2 is degraded by proteases into smaller inactive peptide fragments. No pharmacologically active metabolites have been identified.

Open Questions

  • Long-term cortisol effects: The clinical significance of chronic low-grade cortisol elevation from GHRP-2 use has not been formally studied.
  • Optimal GHRP/GHRH ratio: The ideal dosing ratio when combining GHRP-2 with a GHRH has not been formally established in humans.
11 · Frequently Asked Questions (FAQ)

Frequently Asked Questions (FAQ).

1. What is the difference between GHRP-2 and GHRP-6? Both are GHRPs that stimulate GH release via GHSR-1a, but GHRP-2 is more potent and produces less hunger than GHRP-6. GHRP-6 is preferred when appetite stimulation is a desired benefit.

2. Does GHRP-2 need to be injected on an empty stomach? Yes. Insulin and somatostatin both blunt the GH pulse. Inject at least 2 hours after your last meal and wait 30-60 minutes before eating.

3. How does GHRP-2 compare to Ipamorelin? GHRP-2 produces a larger GH pulse but also elevates cortisol and prolactin, which Ipamorelin does not. Ipamorelin is preferred for long-term use; GHRP-2 is preferred when maximum GH output is desired.

4. Can GHRP-2 cause gynecomastia? GHRP-2 elevates prolactin, which in high concentrations can contribute to gynecomastia. Monitoring prolactin levels is recommended.

5. Is GHRP-2 approved for medical use? GHRP-2 (as Pralmorelin) is approved in Japan as a diagnostic agent for testing pituitary GH reserve. It is not approved for therapeutic use in the US, EU, UK, Canada, or Australia.

6. What is the saturation dose for GHRP-2? Research suggests approximately 1-2 mcg/kg body weight is the maximally effective dose. Doses above this threshold do not produce proportionally greater GH release.

7. Is GHRP-2 detectable in drug testing? Yes. GHRP-2 is banned by WADA and is detectable in urine and blood samples. [10]

12 · International Regulatory Status

International Regulatory Status.

Country/RegionRegulatory BodyStatusNotes
United StatesFDAUnapprovedResearch chemical only.
United KingdomMHRAUnapprovedNot licensed for medical use.
European UnionEMAUnapprovedNot approved for human use.
CanadaHealth CanadaUnapprovedNot approved for human use.
AustraliaTGARestrictedSchedule 4 (Prescription Only Medicine).
JapanPMDAApproved (Diagnostic)Pralmorelin approved for GH stimulation testing.
Global SportWADABannedProhibited at all times under S2 (Peptide Hormones).
13 · The Decision Tree

The Decision Tree.

START: Are you a WADA-tested athlete?
├── YES: STOP. GHRP-2 is banned.
└── NO: Do you have elevated cortisol or prolactin?
    ├── YES: Consider Ipamorelin instead (no cortisol/prolactin effect).
    └── NO: Are you new to peptides?
        ├── YES: Start with Ipamorelin first; GHRP-2 is not a beginner compound.
        └── NO: Is your goal a potent GH pulse with moderate side effects?
            ├── NO: Consider Ipamorelin for minimal side effects or Hexarelin for maximum potency.
            └── YES: GHRP-2 is appropriate. Stack with CJC-1295 (No DAC) for synergy.
14 · Schema.org Structured Data

Schema.org Structured Data.

{
  "@context": "https://schema.org",
  "@type": "MedicalEntity",
  "name": "GHRP-2",
  "alternateName": ["Pralmorelin", "KP-102"],
  "description": "A synthetic hexapeptide GHRP that stimulates growth hormone release via GHSR-1a binding. Approved as a diagnostic agent in Japan."
}
{
  "@context": "https://schema.org",
  "@type": "FAQPage",
  "mainEntity": [
    {
      "@type": "Question",
      "name": "What is the difference between GHRP-2 and GHRP-6?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Both are GHRPs that stimulate GH release via GHSR-1a, but GHRP-2 is more potent and produces less hunger than GHRP-6. GHRP-6 is preferred when appetite stimulation is a desired benefit."
      }
    },
    {
      "@type": "Question",
      "name": "Does GHRP-2 need to be injected on an empty stomach?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Yes. Insulin and somatostatin both blunt the GH pulse. Inject at least 2 hours after your last meal and wait 30-60 minutes before eating."
      }
    },
    {
      "@type": "Question",
      "name": "Is GHRP-2 approved for medical use?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "GHRP-2 (as Pralmorelin) is approved in Japan as a diagnostic agent for testing pituitary GH reserve. It is not approved for therapeutic use in the US, EU, UK, Canada, or Australia."
      }
    },
    {
      "@type": "Question",
      "name": "Can GHRP-2 cause gynecomastia?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "GHRP-2 elevates prolactin, which in high concentrations can contribute to gynecomastia. Monitoring prolactin levels is recommended."
      }
    },
    {
      "@type": "Question",
      "name": "What is the saturation dose for GHRP-2?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Research suggests approximately 1-2 mcg/kg body weight is the maximally effective dose. Doses above this threshold do not produce proportionally greater GH release."
      }
    },
    {
      "@type": "Question",
      "name": "How does GHRP-2 compare to Ipamorelin?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "GHRP-2 produces a larger GH pulse but also elevates cortisol and prolactin, which Ipamorelin does not. Ipamorelin is preferred for long-term use; GHRP-2 is preferred when maximum GH output is desired."
      }
    },
    {
      "@type": "Question",
      "name": "Is GHRP-2 detectable in drug testing?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Yes. GHRP-2 is banned by WADA and is detectable in urine and blood samples. ^[10]"
      }
    }
  ]
}
15 · References

What we cited.

  1. Bowers, C. Y., Momany, F. A., Reynolds, G. A., & Hong, A. (1984). On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology, 114(5), 1537-1545. PMID: 6324103
  2. Arvat, E., Maccario, M., Di Vito, L., Broglio, F., Benso, A., Gottero, C., ... & Ghigo, E. (2001). Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. Journal of Clinical Endocrinology & Metabolism, 86(3), 1169-1174. PMID: 11238504
  3. Katakami, H., Shimizu, K., Ikeda, T., Kato, Y., & Imura, H. (1994). Pralmorelin (GHRP-2): A new growth hormone-releasing peptide for diagnostic use. Endocrine Journal, 41(5), 549-554.
  4. Pong, S. S., Chaung, L. Y., Dean, D. C., Nargund, R. P., Patchett, A. A., & Smith, R. G. (1996). Identification of a new G-protein-linked receptor for growth hormone secretagogues. Molecular Endocrinology, 10(1), 57-61. PMID: 8838145
  5. Arvat, E., Di Vito, L., Broglio, F., Papotti, M., Muccioli, G., Dieguez, C., ... & Ghigo, E. (2000). Preliminary evidence that Ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans. Journal of Endocrinological Investigation, 23(8), 493-495. PMID: 11021769
  6. Bowers, C. Y. (1998). Growth hormone-releasing peptide (GHRP). Cellular and Molecular Life Sciences, 54(12), 1316-1329. PMID: 9869414
  7. Ghigo, E., Arvat, E., Muccioli, G., & Camanni, F. (1997). Growth hormone-releasing peptides. European Journal of Endocrinology, 136(5), 445-460. PMID: 9186261
  8. Smith, R. G., Van der Ploeg, L. H., Howard, A. D., Feighner, S. D., Cheng, K., Hickey, G. J., ... & Pong, S. S. (1997). Peptidomimetic regulation of growth hormone secretion. Endocrine Reviews, 18(5), 621-645. PMID: 9331547
  9. Imbimbo, B. P., Mant, T., Edwards, M., Amin, D., Dalton, N., Boutignon, F., ... & Deghenghi, R. (1994). Growth hormone-releasing activity of hexarelin in humans: a dose-response study. European Journal of Clinical Pharmacology, 46(5), 421-425. PMID: 7957536
  10. Semenistaya, E., Zvereva, I., Thomas, A., Thevis, M., Krotov, G., & Rodchenkov, G. (2015). Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin. Drug Testing and Analysis, 7(11-12), 1036-1043. PMID: 26010999
  11. Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561. PMID: 9849822 --- Disclaimer: This document is for informational and harm-reduction purposes only. Always consult a qualified healthcare provider before beginning any peptide protocol.

Track your protocol.

Epti is the first training app built around your peptide protocol.